The HCV serum proteome: A search for fibrosis protein markers

Journal of Viral Hepatitis

Volumn 16, Issue 6, 2009, Pages 418-429

  Cheung, K J ^a   Tilleman, K ^b   Deforce, D ^b   Colle, I ^a   Van Vlierberghe, H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Hepatitis C virus; Liver fibrosis; METAVIR; Proteomics; Serum

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA2 GLYCOPROTEIN; BINDING PROTEIN; BIOLOGICAL MARKER; FETUIN A; GLYCOPROTEIN IB ALPHA; HAPTOGLOBIN; HEMOPEXIN; MAC 2 BINDING PROTEIN; PROTEOME; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOME; SERUM;

EID: 65449190146     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01083.x     Document Type: Article

References (43)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003 362 : 2095 2100. (Pubitemid 38035201)
2. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004 10 : S21 S29. (Pubitemid 38380782)
3. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003 38 : 427 432. (Pubitemid 36606313)
4. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 : 986 992.
5. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 2075. (Pubitemid 32322537)
6. Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004 41 : 935 942. (Pubitemid 39575660)
7. Patel K, Nelson DR, Rockey DC et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008 6 : 242 247.
8. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 526. (Pubitemid 36919874)
9. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004 10 : 429 434. (Pubitemid 38508524)
10. Hanash S. Disease proteomics. Nature 2003 422 : 226 232. (Pubitemid 36362760)
11. Vitzthum F, Behrens F, Anderson NL, Shaw JH. Proteomics: from basic research to diagnostic application. A review of requirements and needs. J Proteome Res 2005 4 : 1086 1097. (Pubitemid 41208666)
12. Morra R, Munteanu M, Bedossa P et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007 26 : 847 858. (Pubitemid 47346704)
13. Poon TC, Hui AY, Chan HL et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005 51 : 328 335. (Pubitemid 40175802)
14. Diamond DL, Jacobs JM, Paeper B et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007 46 : 649 657. (Pubitemid 47436109)
15. Rabilloud T, Valette C, Lawrence JJ. Sample application by in-gel rehydration improves the resolution of two-dimensional electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis 1994 15 : 1552 1558.
16. Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R, Engel J. Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem 2002 277 : 15690 15696.
17. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996 56 : 4530 4534. (Pubitemid 26330466)
18. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001 91 : 167 172. (Pubitemid 32041735)
19. Grassadonia A, Tinari N, Iurisci I et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004 19 : 551 556.
20. Groschel B, Braner JJ, Funk M et al. Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol 2000 20 : 117 122. (Pubitemid 30314316)
21. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2001 39 : 961 965. (Pubitemid 33062248)
22. Koopmann J, Thuluvath PJ, Zahurak ML et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004 101 : 1609 1615. (Pubitemid 39318908)
23. Marchetti A, Tinari N, Buttitta F et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002 62 : 2535 2539. (Pubitemid 34462731)
24. Ohshima S, Kuchen S, Seemayer CA et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003 48 : 2788 2795. (Pubitemid 37280607)
25. Anderson GJ, Frazer DM. Hepatic iron metabolism. Semin Liver Dis 2005 25 : 420 432. (Pubitemid 41741259)
26. Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta 2001 312 : 13 23. (Pubitemid 32913576)
27. Bakker WW, Borghuis T, Harmsen MC et al. Protease activity of plasma hemopexin. Kidney Int 2005 68 : 603 610. (Pubitemid 43323115)
28. Janig E, Stumptner C, Fuchsbichler A, Denk H, Zatloukal K. Interaction of stress proteins with misfolded keratins. Eur J Cell Biol 2005 84 : 329 339. (Pubitemid 40353072)
29. Kalabay L, Graf L, Voros K et al. Human serum fetuin A/alpha2HS- glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scores. BMC Gastroenterol 2007 7 : 15. (Pubitemid 46614507)
30. Kalabay L, Jakab L, Prohaszka Z et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 2002 14 : 389 394. (Pubitemid 34439037)
31. Kakisaka T, Kondo T, Okano T et al. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2007 852 : 257 267. (Pubitemid 46830120)
32. Sun D, Kar S, Carr BI. Differentially expressed genes in TGF-beta 1 sensitive and resistant human hepatoma cells. Cancer Lett 1995 89 : 73 79.
33. Heitner JC, Koy C, Kreutzer M, Gerber B, Reimer T, Glocker MO. Differentiation of HELLP patients from healthy pregnant women by proteome analysis - on the way towards a clinical marker set. J Chromatogr B Analyt Technol Biomed Life Sci 2006 840 : 10 19. (Pubitemid 44108804)
34. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007 53 : 1792 1799. (Pubitemid 47509672)
35. White IR, Patel K, Symonds WT et al. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med 2007 5 : 33. (Pubitemid 47386483)
36. Kittl EM, Hofmann J, Hartmann G et al. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med 2000 38 : 205 208. (Pubitemid 30386689)
37. D'Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S. 90K (Mac-2 BP) in human milk. Clin Exp Immunol 1996 104 : 543 546. (Pubitemid 26171568)
38. Tolosano E, Fagoonee S, Hirsch E et al. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood 2002 100 : 4201 4208. (Pubitemid 35402055)
39. Gravel P, Walzer C, Aubry C et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochem Biophys Res Commun 1996 220 : 78 85. (Pubitemid 26106802)
40. Kalabay L, Nemesanszky E, Csepregi A et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol 2004 16 : 51 54. (Pubitemid 38054626)
41. Verma-Gandhu M, Peterson MR, Peterson TC. Effect of fetuin, a TGFbeta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis. Eur J Pharmacol 2007 572 : 220 227. (Pubitemid 47429640)
42. Parent R, Beretta L. Proteomics in the study of liver pathology. J Hepatol 2005 43 : 177 183. (Pubitemid 40805289)
43. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Proteomics in liver fibrosis is more than meets the eye. Eur J Gastroenterol Hepatol 2008 20 : 450 464.